Cell Signaling Technology Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb
News Feb 08, 2008
Cell Signaling Technology, Inc. (CST) announced the continuation of a research agreement with Bristol-Myers Squibb Company under which CST will employ its patented PhosphoScan® technology in the cell and tumor phospho-profiling of a Bristol-Myers Squibb small-molecule kinase inhibitor.
The PhosphoScan® profiling research project builds on a successful evaluation project between the two companies, which was completed in March 2007, and will involve in vivo phosphorylation profiling of kinase inhibitor response profiles in xenograft tumor models.
PhosphoScan® proteomics is a patented strategy for broad profiling of phosphorylation in cells and tissues. The PhosphoSignatures™ generated with the Bristol-Myers Squibb compound will be analyzed and understood within the context of CST’s PhosphoSignature™ database covering hundreds of cancer cell lines and human tumors.
PhosphoScan® profiling involves immunoaffinity purification and tandem mass spectroscopy and its effectiveness in kinase target and biomarker discover in cancer was illustrated most recently in the journal Cell.
“Our PhosphoScan® profiling research with Bristol-Myers Squibb has been very successful and we are glad to have the opportunity to extend that research in analysis of Bristol-Myers Squibb’s kinase inhibitors in tumor models,” said Christopher Bunker, CST’s Director of Business Development.
Dr. Bunker went on to say, “The application of PhosphoScan® to both cell and tumor models is an effective strategy by which to validate PhosphoSignature™ discoveries enabling the opportunity to develop biomarker assays specific for Bristol-Myers Squibb targeted small molecule therapeutics.”
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.